No Data
No Data
Barclays Maintains Overweight on Exact Sciences, Raises Price Target to $75
What to Expect From Neurocrine Biosciences's Earnings
Earnings Outlook For Vertex Pharmaceuticals
Liquidia Surges 15% as Court Clears Way for Yutrepia Launch
RBC Capital Maintains Outperform on Amgen, Lowers Price Target to $320
Amgen Analyst Ratings